New PDUFA Deal Sets Aside FDA Funds to Rehire Drug Reviewers

· Health · United States

Top pharmaceutical trade groups say the new Prescription Drug User Fee Act (PDUFA) agreement includes a dedicated pool of money for the FDA to replenish its ranks of drug reviewers after recent layoffs at HHS, according to Endpoints News. The PDUFA framework, renegotiated periodically, sets the fees drugmakers pay to fund the FDA's human drug review process. Separately, HHS has launched a new plan to strengthen vaccine injury research and reporting, spearheaded by vaccine skeptic Robert F. Kennedy Jr., involving a new NIH clinic, an updated monitoring system and reimbursements for doctors who report suspected side effects. The two developments signal shifting priorities in U.S. drug regulation and public health oversight. The PDUFA deal aims to stabilize review capacity; the vaccine injury initiative expands reporting and research infrastructure.

Why it matters：FDA review capacity and vaccine safety monitoring are foundational to drug development timelines and public confidence; funding to rehire reviewers could ease approval bottlenecks, while the new vaccine injury initiative may reshape how side effects are researched and reported.

Key points

  • The new PDUFA agreement creates a dedicated fund for the FDA to rehire drug reviewers after HHS layoffs.
  • HHS is launching a vaccine injury research and reporting plan led by Robert F. Kennedy Jr.
  • The plan includes a new NIH clinic, an updated monitoring system and reimbursements for doctors reporting suspected side effects.

Sources (original reporting)

More stories from this day